Global Agitation in Delirium Management Market, By Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, Others), Route of Administration (Oral, Intramuscular, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Agitation in Delirium Management Market
Global agitation in delirium management market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.1% in the above mentioned forecast period.
Delirium is a serious disturbance in the mental abilities which causes confusion and reduced awareness of the environment. It occurs suddenly over a period of hours or days. The person may experience trouble in paying attention or thinking clearly. It is sometimes called acute confusional state. Agitation is a symptom of delirium. It occurs due to symptoms such as pain or breathlessness.
Rise in the prevalence of delirium, increasing geriatric population, growing government initiatives, advancement in treatment options, rising awareness about agitation in delirium and its management are the factors that will expand the global agitation in delirium management market.
Rising research and development activities, ongoing clinical trials, and growing focus of major pharmaceutical companies towards novel treatment therapies will provide beneficial opportunities for the global agitation in delirium management market in the forecast period of 2021-2028.
Availability of non-pharmacological alternatives, high cost of medication, and increasing product recalls are the factors that will hamper the market growth and will further challenge the global agitation in delirium management market in the forecast period mentioned above.
This Agitation in delirium management market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global agitation in delirium management market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Agitation in Delirium Management Market Scope and Market Size
The Agitation in delirium management market is segmented on the basis of drug, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of drug, the agitation in delirium management market is segmented into first-generation antipsychotics, second-generation antipsychotics, benzodiazepine, and others.
- On the basis of route of administration, the agitation in delirium management market is segmented into oral, intramuscular, and others.
- On the basis of end-users, the agitation in delirium management market is segmented into clinic, hospital, and others.
- The agitation in delirium management market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.
Global Agitation in Delirium Management Market Country Level Analysis
Global agitation in delirium management market is analyzed, and market size information is provided by the country, drug, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global agitation in delirium management market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the agitation in delirium management market due to the increasing research and development activities by major key players, well-developed healthcare sector, increasing prevalence of disease, and increasing awareness towards health in this region. Global agitation in delirium management market in the Asia-Pacific and Europe is expected to grow during the forecast period due to the increasing prevalence of cancer, rise in research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Global agitation in delirium management market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Agitation in Delirium Management Market Share Analysis
Global agitation in delirium management market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global agitation in delirium management market.
The major players covered in the global agitation in delirium management market report are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Pfizer Inc., Fresenius Kabi AG, Novartis AG, Akorn, Incorporated, Zydus Cadila, BioXcel Therapeutics, Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
For Instance:
On October 26th, 2020, BioXcel Therapeutics, Inc. received the clearance for its Investigational New Drug (IND) application for BXCL501 from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA). The received clearance is for the treatment of agitation associated with delirium, and currently it’s under Phase 2 of clinical trial.
SKU-